Relmada Therapeutics (NASDAQ:RLMD) said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer and strengthening its balance sheet through a private financing.
On the company’s first-quarter earnings call, Chief Executive Officer Dr. Sergio Traversa said the company has made “excellent progress” this year, citing 12-month efficacy data for NDV-01, alignment with the U.S. Food and Drug Administration on the planned registrational program, a new provisional patent filing and completion of a $160 million private placement financing.
